Gene therapy comes of age

Science. 2018 Jan 12;359(6372):eaan4672. doi: 10.1126/science.aan4672.


After almost 30 years of promise tempered by setbacks, gene therapies are rapidly becoming a critical component of the therapeutic armamentarium for a variety of inherited and acquired human diseases. Gene therapies for inherited immune disorders, hemophilia, eye and neurodegenerative disorders, and lymphoid cancers recently progressed to approved drug status in the United States and Europe, or are anticipated to receive approval in the near future. In this Review, we discuss milestones in the development of gene therapies, focusing on direct in vivo administration of viral vectors and adoptive transfer of genetically engineered T cells or hematopoietic stem cells. We also discuss emerging genome editing technologies that should further advance the scope and efficacy of gene therapy approaches.

Publication types

  • Review

MeSH terms

  • Animals
  • Gene Editing
  • Gene Transfer Techniques
  • Genetic Diseases, Inborn / therapy
  • Genetic Engineering
  • Genetic Therapy* / adverse effects
  • Genetic Vectors
  • Hematologic Diseases / therapy
  • Humans
  • Neoplasms / therapy
  • Neuromuscular Diseases / therapy
  • Translational Research, Biomedical